Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium longum biovar infantis CECT7210
- Development stage
- Unknown
- Lead developer
- Laboratorios Ordesa
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium longum biovar infantis CECT7210 is a probiotic bacterial strain isolated from the feces of a healthy, breast-fed infant. Developed by Laboratorios Ordesa, it is specifically selected for its ability to survive gastrointestinal transit and adhere to the intestinal mucosa. The strain is incorporated into infant formulas to promote a healthy gut microbiome, reduce the incidence of gastrointestinal infections, and decrease the severity of diarrhea in infants. Its mechanism involves competitive exclusion of pathogens, production of antimicrobial substances, and modulation of the host immune system.
- Brand names
- Blemil PlusBlevit
- Other names
- Bifidobacterium longum CECT7210B. infantis CECT7210Bifidobacterium longum biovar infantis CECT7210
Beyond the preview
Go deeper on bifidobacterium longum biovar infantis CECT7210.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium longum biovar infantis CECT7210.